| NCT07020819 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | NOT_YET_RECRUITING | PHASE3 | 2025-06 | 2028-06 | 2026-12 |
| NCT06510816 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) | RECRUITING | PHASE3 | 2024-07-30 | 2027-10-31 | 2026-10-31 |
| NCT05780515 | A Study of ANX009 in Adult Participants With Lupus Nephritis | COMPLETED | PHASE1 | 2022-08-09 | 2023-10-31 | 2023-08-31 |
| NCT05521269 | Dose Study of ANX1502 in Healthy Volunteers | COMPLETED | PHASE1 | 2022-06-27 | 2024-11-19 | 2024-11-19 |
| NCT05288881 | Single Ascending Dose Study of ANX105 | COMPLETED | PHASE1 | 2022-02-28 | 2023-06-19 | 2023-06-19 |
| NCT04691570 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) | COMPLETED | PHASE2 | 2021-11-10 | 2023-01-17 | 2023-01-17 |
| NCT04656561 | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy | COMPLETED | PHASE2 | 2021-02-26 | 2023-09-13 | 2023-03-28 |
| NCT04569435 | Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | PHASE2 | 2021-01-15 | 2024-04-23 | 2024-01-10 |
| NCT04701164 | Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome | COMPLETED | PHASE3 | 2020-12-17 | 2024-04-20 | 2024-04-20 |
| NCT04535752 | A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV) | COMPLETED | PHASE1 | 2020-10-30 | 2021-06-26 | 2021-06-26 |
| NCT04514367 | An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease | COMPLETED | PHASE2 | 2020-08-17 | 2022-01-28 | 2022-01-28 |
| NCT04035135 | A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) | COMPLETED | PHASE1 | 2020-01-29 | 2021-05-19 | 2021-05-19 |
| NCT04188015 | Study of ANX007 in Participants With Primary Open-angle Glaucoma | COMPLETED | PHASE1 | 2018-07-25 | 2019-06-03 | 2019-06-03 |
| NCT03488550 | Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma | COMPLETED | PHASE1 | 2018-03-23 | 2018-08-03 | 2018-08-03 |
| NCT03010046 | Single Dose Study of ANX005 in Healthy Volunteers | TERMINATED | PHASE1 | 2016-12 | 2018-06 | 2018-06 |